Experienced in Esophagitis

Signe Friesland

Neck, 
Stockholm, AB, SE 
Experienced in Esophagitis
Neck, 
Stockholm, AB, SE 
OverviewLocationsClinical Research

Overview

Signe Friesland practices in Stockholm, Sweden. Ms. Friesland is rated as an Experienced expert by MediFind in the treatment of Esophagitis. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Adenoid Cystic Carcinoma, Lung Cancer, and Tongue Cancer.

Her clinical research consists of co-authoring 49 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Esophagitis.

Gender
Female

Locations

Neck, Stockholm, AB, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Brigatinib, Alectinib
Study Phase: Phase 3
A Randomized Multicenter Phase III Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.
A Randomized Multicenter Phase III Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.
Enrollment Status: Completed
Publish Date: September 02, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

49 Total Publications

Validated prediction of xerostomia in a real-world population: a step toward model-guided radiotherapy.
Validated prediction of xerostomia in a real-world population: a step toward model-guided radiotherapy.
Journal: Acta oncologica (Stockholm, Sweden)
Published: May 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Friesland's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile